Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis
Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis
复制标题
DOI：
10.1096/fasebj.13.6.647
复制
发表时间：
1999-04-01
期刊：
影响因子：
4.8
通讯作者：
Schettini, G
中科院分区：
文献类型：
--
作者：
Albini, A;Florio, T;Schettini, G
生长抑素及其类似物对SST受体阳性的内分泌肿瘤有抑制作用，但对非内分泌肿瘤的作用及其机制尚不清楚。生长抑素能有效地抑制裸鼠Kaposi肉瘤移植瘤的生长，但在体外，肿瘤细胞不表达任何已知的生长抑素受体，也不被生长抑素抑制。组织学检查显示，与对照组相比，生长抑素治疗组的肿瘤血管生成有限。在体内实验中，生长抑素是一种有效的血管生成抑制剂。在体外，生长抑素抑制内皮细胞的生长和侵袭。生长抑素也抑制了单核细胞的迁移，单核细胞是血管生成级联反应的重要中介。两种细胞均表达生长抑素受体mRNAs。这些数据表明，生长抑素是一种有效的抗肿瘤血管生成化合物，直接影响内皮细胞和单核细胞。考虑到这些数据，有争议的生长抑素在肿瘤治疗中的作用和治疗方案的设计应该重新审查。
Somatostatin and its analogs are active in the inhibition of SST receptor-positive endocrine neoplasms, but their activity and mechanism in non endocrine tumors is not clear. Somatostatin potently inhibited growth of a Kaposi's sarcoma xenograft in nude mice, yet in vitro the tumor cells did not express any known somatostatin receptors and were not growth inhibited by somatostatin. Histological examination revealed limited vascularization in the somatostatin-treated tumors as compared with the controls. Somatostatin was a potent inhibitor of angiogenesis in an in vivo assay. In vitro, somatostatin inhibited endothelial cell growth and invasion. Migration of monocytes, important mediators of the angiogenic cascade, was also inhibited by somatostatin. Both cells types expressed somatostatin receptor mRNAs. These data demonstrate that somatostatin is a potent antitumor angiogenesis compound directly affecting both endothelial and monocytic cells. The debated function of somatostatin in tumor treatment and the design of therapeutic protocols should be reexamined considering these data.